Applewhite and Sherman Respond
[...]some participants in our pilot project requested intranasal naloxone during our follow-up phone calls.[...]the first Food and Drug Administration-approved intranasal version of naloxone, Narcan nasal spray, which was approved during our pilot project, costs $75 dollars even at its reduced rate...
Gespeichert in:
| Veröffentlicht in: | American journal of public health (1971) 2017-07, Vol.107 (7), p.e1-e2 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e2 |
|---|---|
| container_issue | 7 |
| container_start_page | e1 |
| container_title | American journal of public health (1971) |
| container_volume | 107 |
| creator | Applewhite, Dinah P Sherman, Susan G |
| description | [...]some participants in our pilot project requested intranasal naloxone during our follow-up phone calls.[...]the first Food and Drug Administration-approved intranasal version of naloxone, Narcan nasal spray, which was approved during our pilot project, costs $75 dollars even at its reduced rate for nonprofits.1 Even more expensive is Evzio, an autoinjector formulation of naloxone that costs over $4000, reflecting a 500% price increase over a two-year period.2 We have weighed the costs and benefits of different naloxone formulations and have decided to continue to use injectable naloxone so that we can meet the high demand of the community.Susan G. Sherman is with the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Correspondence should be sent to Dinah P. Applewhite, c/o Internal Medicine Residency Program, Massachusetts General Hospital, 55 Fruit St, Gray 7-730, Boston, MA 02114 (e-mail: dapplewhite@partners.org). |
| doi_str_mv | 10.2105/AJPH.2017.303812 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5463224</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1907323443</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-14d639c8f16dfa5b829ef1e0f76f16d5faa7e0120a995a6ce870f1cada14093</originalsourceid><addsrcrecordid>eNpdkE1Lw0AQhhdRbK3ePZWCFy-pM_uV7EUoRa1SUKz3ZZvs2pR8mU0U_70JraKedth55mXmIeQcYUoRxNXs4WkxpYDhlAGLkB6QIQqOAQCPDskQQEFXMzkgJ95vARCVwGMyoJFQEEkckvGsqjL7sUkbOzFFMlltbJ2bYvJsfVUWySk5cibz9mz_jsjq9uZlvgiWj3f389kyiFkYNgHyRDIVRw5l4oxYR1RZhxZcKPsv4YwJLSAFo5QwMrZRCA5jkxjkoNiIXO9Sq3ad2yS2RVObTFd1mpv6U5cm1X87RbrRr-W7FlwySnkXcLkPqMu31vpG56mPbZaZwpat16ggZJRxzjr04h-6Ldu66I7rKBoq0SXKjoIdFdel97V1P8sg6F697tXrXr3eqe9Gxr-P-Bn4ds2-ADpHfdI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1927956326</pqid></control><display><type>article</type><title>Applewhite and Sherman Respond</title><source>PAIS Index</source><source>Business Source Complete</source><source>Education Source</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Applewhite, Dinah P ; Sherman, Susan G</creator><creatorcontrib>Applewhite, Dinah P ; Sherman, Susan G</creatorcontrib><description>[...]some participants in our pilot project requested intranasal naloxone during our follow-up phone calls.[...]the first Food and Drug Administration-approved intranasal version of naloxone, Narcan nasal spray, which was approved during our pilot project, costs $75 dollars even at its reduced rate for nonprofits.1 Even more expensive is Evzio, an autoinjector formulation of naloxone that costs over $4000, reflecting a 500% price increase over a two-year period.2 We have weighed the costs and benefits of different naloxone formulations and have decided to continue to use injectable naloxone so that we can meet the high demand of the community.Susan G. Sherman is with the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Correspondence should be sent to Dinah P. Applewhite, c/o Internal Medicine Residency Program, Massachusetts General Hospital, 55 Fruit St, Gray 7-730, Boston, MA 02114 (e-mail: dapplewhite@partners.org).</description><identifier>ISSN: 0090-0036</identifier><identifier>EISSN: 1541-0048</identifier><identifier>DOI: 10.2105/AJPH.2017.303812</identifier><identifier>PMID: 28590861</identifier><language>eng</language><publisher>United States: American Public Health Association</publisher><subject>AJPH Letters and Responses ; Community Health ; Cost benefit analysis ; Costs ; Drug overdose ; Drugs ; Epidemiology ; FDA approval ; Food ; Formulations ; Health care policy ; Internal medicine ; Naloxone ; Nose ; Other Health Financing ; Pilot projects ; Prevention ; Public health ; Surveys ; Telephone calls</subject><ispartof>American journal of public health (1971), 2017-07, Vol.107 (7), p.e1-e2</ispartof><rights>Copyright American Public Health Association Jul 2017</rights><rights>American Public Health Association 2017 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c377t-14d639c8f16dfa5b829ef1e0f76f16d5faa7e0120a995a6ce870f1cada14093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463224/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463224/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,27847,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28590861$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Applewhite, Dinah P</creatorcontrib><creatorcontrib>Sherman, Susan G</creatorcontrib><title>Applewhite and Sherman Respond</title><title>American journal of public health (1971)</title><addtitle>Am J Public Health</addtitle><description>[...]some participants in our pilot project requested intranasal naloxone during our follow-up phone calls.[...]the first Food and Drug Administration-approved intranasal version of naloxone, Narcan nasal spray, which was approved during our pilot project, costs $75 dollars even at its reduced rate for nonprofits.1 Even more expensive is Evzio, an autoinjector formulation of naloxone that costs over $4000, reflecting a 500% price increase over a two-year period.2 We have weighed the costs and benefits of different naloxone formulations and have decided to continue to use injectable naloxone so that we can meet the high demand of the community.Susan G. Sherman is with the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Correspondence should be sent to Dinah P. Applewhite, c/o Internal Medicine Residency Program, Massachusetts General Hospital, 55 Fruit St, Gray 7-730, Boston, MA 02114 (e-mail: dapplewhite@partners.org).</description><subject>AJPH Letters and Responses</subject><subject>Community Health</subject><subject>Cost benefit analysis</subject><subject>Costs</subject><subject>Drug overdose</subject><subject>Drugs</subject><subject>Epidemiology</subject><subject>FDA approval</subject><subject>Food</subject><subject>Formulations</subject><subject>Health care policy</subject><subject>Internal medicine</subject><subject>Naloxone</subject><subject>Nose</subject><subject>Other Health Financing</subject><subject>Pilot projects</subject><subject>Prevention</subject><subject>Public health</subject><subject>Surveys</subject><subject>Telephone calls</subject><issn>0090-0036</issn><issn>1541-0048</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>7TQ</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkE1Lw0AQhhdRbK3ePZWCFy-pM_uV7EUoRa1SUKz3ZZvs2pR8mU0U_70JraKedth55mXmIeQcYUoRxNXs4WkxpYDhlAGLkB6QIQqOAQCPDskQQEFXMzkgJ95vARCVwGMyoJFQEEkckvGsqjL7sUkbOzFFMlltbJ2bYvJsfVUWySk5cibz9mz_jsjq9uZlvgiWj3f389kyiFkYNgHyRDIVRw5l4oxYR1RZhxZcKPsv4YwJLSAFo5QwMrZRCA5jkxjkoNiIXO9Sq3ad2yS2RVObTFd1mpv6U5cm1X87RbrRr-W7FlwySnkXcLkPqMu31vpG56mPbZaZwpat16ggZJRxzjr04h-6Ldu66I7rKBoq0SXKjoIdFdel97V1P8sg6F697tXrXr3eqe9Gxr-P-Bn4ds2-ADpHfdI</recordid><startdate>201707</startdate><enddate>201707</enddate><creator>Applewhite, Dinah P</creator><creator>Sherman, Susan G</creator><general>American Public Health Association</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>0U~</scope><scope>1-H</scope><scope>3V.</scope><scope>7RV</scope><scope>7TQ</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>88J</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DHY</scope><scope>DON</scope><scope>DPSOV</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K60</scope><scope>K6~</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KC-</scope><scope>L.-</scope><scope>L.0</scope><scope>LK8</scope><scope>M0C</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2L</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M2R</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PATMY</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>PYCSY</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201707</creationdate><title>Applewhite and Sherman Respond</title><author>Applewhite, Dinah P ; Sherman, Susan G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-14d639c8f16dfa5b829ef1e0f76f16d5faa7e0120a995a6ce870f1cada14093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>AJPH Letters and Responses</topic><topic>Community Health</topic><topic>Cost benefit analysis</topic><topic>Costs</topic><topic>Drug overdose</topic><topic>Drugs</topic><topic>Epidemiology</topic><topic>FDA approval</topic><topic>Food</topic><topic>Formulations</topic><topic>Health care policy</topic><topic>Internal medicine</topic><topic>Naloxone</topic><topic>Nose</topic><topic>Other Health Financing</topic><topic>Pilot projects</topic><topic>Prevention</topic><topic>Public health</topic><topic>Surveys</topic><topic>Telephone calls</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Applewhite, Dinah P</creatorcontrib><creatorcontrib>Sherman, Susan G</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>Global News & ABI/Inform Professional</collection><collection>Trade PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>PAIS Index</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>PAIS International</collection><collection>PAIS International (Ovid)</collection><collection>Politics Collection</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Politics Collection</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Professional Standard</collection><collection>ProQuest Biological Science Collection</collection><collection>ABI/INFORM Global</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Political Science Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Social Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Environmental Science Database</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>Environmental Science Collection</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of public health (1971)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Applewhite, Dinah P</au><au>Sherman, Susan G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Applewhite and Sherman Respond</atitle><jtitle>American journal of public health (1971)</jtitle><addtitle>Am J Public Health</addtitle><date>2017-07</date><risdate>2017</risdate><volume>107</volume><issue>7</issue><spage>e1</spage><epage>e2</epage><pages>e1-e2</pages><issn>0090-0036</issn><eissn>1541-0048</eissn><abstract>[...]some participants in our pilot project requested intranasal naloxone during our follow-up phone calls.[...]the first Food and Drug Administration-approved intranasal version of naloxone, Narcan nasal spray, which was approved during our pilot project, costs $75 dollars even at its reduced rate for nonprofits.1 Even more expensive is Evzio, an autoinjector formulation of naloxone that costs over $4000, reflecting a 500% price increase over a two-year period.2 We have weighed the costs and benefits of different naloxone formulations and have decided to continue to use injectable naloxone so that we can meet the high demand of the community.Susan G. Sherman is with the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Correspondence should be sent to Dinah P. Applewhite, c/o Internal Medicine Residency Program, Massachusetts General Hospital, 55 Fruit St, Gray 7-730, Boston, MA 02114 (e-mail: dapplewhite@partners.org).</abstract><cop>United States</cop><pub>American Public Health Association</pub><pmid>28590861</pmid><doi>10.2105/AJPH.2017.303812</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-0036 |
| ispartof | American journal of public health (1971), 2017-07, Vol.107 (7), p.e1-e2 |
| issn | 0090-0036 1541-0048 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5463224 |
| source | PAIS Index; Business Source Complete; Education Source; PubMed Central; Alma/SFX Local Collection |
| subjects | AJPH Letters and Responses Community Health Cost benefit analysis Costs Drug overdose Drugs Epidemiology FDA approval Food Formulations Health care policy Internal medicine Naloxone Nose Other Health Financing Pilot projects Prevention Public health Surveys Telephone calls |
| title | Applewhite and Sherman Respond |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T14%3A17%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Applewhite%20and%20Sherman%20Respond&rft.jtitle=American%20journal%20of%20public%20health%20(1971)&rft.au=Applewhite,%20Dinah%20P&rft.date=2017-07&rft.volume=107&rft.issue=7&rft.spage=e1&rft.epage=e2&rft.pages=e1-e2&rft.issn=0090-0036&rft.eissn=1541-0048&rft_id=info:doi/10.2105/AJPH.2017.303812&rft_dat=%3Cproquest_pubme%3E1907323443%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1927956326&rft_id=info:pmid/28590861&rfr_iscdi=true |